EMA Authorised: Retacrit (epoetin zeta) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Retacrit (epoetin zeta) as a biosimilar epoetin for the treatment of anemia in chronic kidney disease and cancer, among other indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer
• Chronic Kidney Disease

Drugs mentioned

• RETACRIT (EPOETIN ALFA-EPBX)

Snippet

Status: Authorised. Therapeutic area: Anemia;Blood Transfusion, Autologous;Kidney Failure, Chronic;Cancer. MAH: Pfizer Europe MA EEIG. Decision date: 02/03/2026